| abstract |
An agent selected from: (i) dopamine; (ii) a dopamine precursor; (iii) an agonist of the dopamine receptor type 1 family (D1-R agonist); (iv) an antagonist of the dopamine receptor type 2 family (D2-R antagonist); (v) a combination of (i) and (ii); or (vi) a combination of (i), (ii) or (iii) with (iv), down-regulates the suppressive activity of CD4+CD25+ regulatory T cells (Treg) on CD4+CD25- effector T cells (Teff) and is useful in methods and compositions for treating a neurodegenerative condition, disorder or disease other than Parkinson's disease. |